---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-002826"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T04:16:32.485328+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Regeneron reports 2024 prelim EYLEA sales $6B; Libtayo >$1B; Dupixent >1M patients; pipeline updates

## Summary
- EYLEA HD and EYLEA aggregate U.S. net sales $6B for 2024 (+1% YoY); Q4 combined $1.5B (EYLEA HD $305M).
- Libtayo exceeded $1B in 2024 annual net sales; Phase 3 adjuvant CSCC shows 68% risk reduction vs placebo.
- New Truveta collaboration to sequence up to 10M additional individuals; RGC has sequenced ~3M people.
- Preliminary Q4 2024 IPR&D charge ~$14M pre-tax, expected to impact GAAP and non-GAAP EPS by ~$0.11.
- Dupixent now used by over 1M patients globally; linvoseltamab BLA resubmitted with launch anticipated mid-2025.

## SEC filing metadata
- accession: 0001104659-25-002826
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/0001104659-25-002826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465925002826/tm253014d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-002826
- JSON: https://secwatch.observer/filing/0001104659-25-002826.json
- Plain text: https://secwatch.observer/filing/0001104659-25-002826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.